Physician

Brandt L Esplin, MD

According to 2025 Medicare claims, Brandt Esplin, MD (NPI: 1285929430) practices hematology/oncology in the Provo-Orem-Lehi, UT market, with the plurality of this provider's patient population coming from Utah, UT. This provider's primary affiliated billing organization is REVERE HEALTH PC (NPI: 1093764805; TIN: 870281028) and primary practice location at 84604-3305. Esplin is affiliated with the Aledade 201 National MSSP (ACO ID: A5522) and Revere Health Collaborative Network, LLC (ACO ID: D0042), participating under both the MSSP and REACH models.

Esplin's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 619 traditional Medicare patients, billed 204,439 HCPCS/CPT codes, and received $3,885,625 in Medicare payments. The top billing code was J0897 (Injection, denosumab, 1 mg). Part D data shows 1,966 prescription claims across 295 beneficiaries totaling $5,093,358 in drug costs, led by Revlimid (Lenalidomide). DME data shows 60 claims. Open Payments data shows 44 records totaling $1,162. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $15,840 to $3,885,625. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $297,513 to $5,093,358. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	85	196	$15,840
2016	96	218	$17,428
2017	435	70,414	$1,042,905
2018	694	162,931	$2,724,085
2019	610	173,862	$3,422,604
2020	588	180,946	$3,002,927
2021	586	185,016	$2,686,803
2022	603	204,732	$3,135,186
2023	627	176,097	$3,361,292
2024	619	204,439	$3,885,625

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	74	257	$297,513
2016	56	295	$420,150
2017	74	291	$581,872
2018	136	691	$1,459,932
2019	162	1,130	$2,868,815
2020	180	1,269	$4,170,353
2021	219	1,457	$4,452,998
2022	247	1,671	$4,495,010
2023	251	1,809	$4,441,997
2024	295	1,966	$5,093,358

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	12	47	$438
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	63	$7,212
2019	N/R	121	$10,056
2020	N/R	70	$4,014
2021	N/R	29	$2,378
2022	N/R	97	$3,270
2023	N/R	88	$15,418
2024	N/R	60	$2,889

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
J0897	Injection, denosumab, 1 mg	177	16,920	$20
80053	Blood test, comprehensive group of blood chemicals	189	594	$10
96372	Injection of drug or substance under skin or into muscle	234	614	$10
36415	Insertion of needle into vein for collection of blood sample	158	353	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	192	686	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	54	1,477	$784,566
Lenalidomide	Lenalidomide	60	1,589	$696,789
Pomalyst	Pomalidomide	28	784	$519,499
Ibrance	Palbociclib	21	588	$358,524
Kisqali	Ribociclib Succinate	20	560	$319,718

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	12	$1,590
J8521	Capecitabine, oral, 500 mg	N	N/R	21	$597
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	11	$402
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	16	$301

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	44	$1,162	Fennec Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Brandt L. Esplin, MD?

Tedicare shows public-source Medicare data for Brandt L. Esplin, MD (NPI 1285929430), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Brandt L. Esplin, MD have ACO affiliation data?

Brandt L. Esplin, MD is shown with ACO affiliation data for Aledade 201 National MSSP (MSSP, ACO ID A5522) and Revere Health Collaborative Network, LLC (REACH, ACO ID D0042).

What billing organization is linked to Brandt L. Esplin, MD?

Brandt L. Esplin, MD is linked to REVERE HEALTH PC (billing NPI 1093764805) in the available physician profile data.

Does Brandt L. Esplin, MD have Open Payments data?

Brandt L. Esplin, MD has 44 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.